38 results
8-K
EX-99.2
IMCR
Immunocore Holdings plc
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
Largest metastatic lesion OS Hazard ratio M1a (<3.0 cm) 0.36 M1b (3.1-8.0 cm) 0.71 M1c (≥8.1 cm) 0.76
Treatment phase Follow-up 1:1
6-K
EX-99.1
IMCR
Immunocore Holdings plc
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
demonstrated an unprecedented OS benefit with a Hazard Ratio (HR) in the intent-to-treat population favoring KIMMTRAK, HR=0.51 (95% CI: 0.37, 0.71); p
6-K
EX-99.1
IMCR
Immunocore Holdings plc
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
-positive adult patients with previously untreated mUM. KIMMTRAK demonstrated an unprecedented OS benefit with a Hazard Ratio (HR) in the intent-to-treat
6-K
EX-99.1
IMCR
Immunocore Holdings plc
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
with a Hazard Ratio (HR) in the intent-to-treat population favoring KIMMTRAK, HR=0.51 (95% CI: 0.37, 0.71); p< 0.0001, over investigator’s choice (82
6-K
EX-99.4
IMCR
Immunocore Holdings plc
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
estate is located in a Special Flood Hazard Area, Federal Flood Insurance, (iii) within sixty (60) days after such acquisition (or such longer period … a hazard to the health and safety of the owners, occupants or any Persons in the vicinity of any Facility or to the indoor or outdoor environment
6-K
EX-99.3
mr46tmd5kvhx3lw
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
u8x3do9nvadxi8g7zrbt
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
9wfbetnlmk6n8lb
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
goa2q
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.2
6yy a081ibl3j
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.2
ua1pzst7
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.3
10wi8w8n yfm
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.4
zl1dzafcokxztry061k
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
3mpgpc 163qxrkig9ho
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
fszasdwseekjohl r8lf
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
6-K
EX-99.3
3li2ol
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
sei0rssmei03ig
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
424B7
xqvxsqz6n2b4tetky
5 May 22
Prospectus with selling stockholder info
12:00am
F-3ASR
k3wgxz9 mf4n
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
6-K
EX-99.1
99ea8
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm